246 related articles for article (PubMed ID: 38474312)
21. Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer.
Liu J; Zhu T; Liu J; Cui Y; Yang S; Zhao R
Acta Biochim Biophys Sin (Shanghai); 2023 Aug; 55(8):1247-1256. PubMed ID: 37559457
[TBL] [Abstract][Full Text] [Related]
22. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitin Mediated Degradation of EGFR by 17 β-estradiol in Triple Negative MDA-MB-231 (TNBC) Breast Cancer Cells Line.
Khode V; Patil S; Kaveeshwar V; Ruikar K; Bargale A; E S; Patil S
Curr Mol Med; 2022; 22(5):449-457. PubMed ID: 34376133
[TBL] [Abstract][Full Text] [Related]
24. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
Lu Q; Chen W; Ji Y; Liu Y; Xue X
Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
[No Abstract] [Full Text] [Related]
25. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
Fouad MA; Sayed-Ahmed MM; Huwait EA; Hafez HF; Osman AM
BMC Pharmacol Toxicol; 2021 Jan; 22(1):8. PubMed ID: 33509300
[TBL] [Abstract][Full Text] [Related]
26. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
27. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
28. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
29. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells.
Yousefi Sadeghloo A; Khorsandi K; Kianmehr Z
Photochem Photobiol Sci; 2020 Nov; 19(11):1580-1589. PubMed ID: 33030191
[TBL] [Abstract][Full Text] [Related]
31. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
32. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
33. Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways.
Maharjan S; Lee MG; Kim SY; Lee KS; Nam KS
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242455
[TBL] [Abstract][Full Text] [Related]
34. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.
Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R
Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593
[TBL] [Abstract][Full Text] [Related]
35. Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin.
Nguyen PL; Elkamhawy A; Choi YH; Lee CH; Lee K; Cho J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077298
[TBL] [Abstract][Full Text] [Related]
36. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
37. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines.
Pilco-Ferreto N; Calaf GM
Int J Oncol; 2016 Aug; 49(2):753-62. PubMed ID: 27278553
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
39. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
40. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
